Advanced Oncotherapy announces second subscription

Nicolas Serandour, CEO of Advanced Oncotherapy

Advanced Oncotherapy has raised a further £167,500 from new and existing investors through the issue of 670,000 new ordinary shares at 25p per share. The company, which raised £15m from a direct subscription in April, said the second subscription was due to additional investor demand and that the funds raised would contribute to progressing assembly,…

You must be a HM Subscriber to view this content.

Subscribe Now »